Towards a safe and effective chlamydial vaccine: Lessons from the eye

Vaccine

Volumn 32, Issue 14, 2014, Pages 1572-1578

  Mabey, David C W ^a   Hu, Victor ^a   Bailey, Robin L ^a   Burton, Matthew J ^a   Holland, Martin J ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Chlamydia; Immunopathology; Protective immunity; Trachoma; Vaccine

Indexed keywords

BACTERIAL VACCINE; CHLAMYDIAL VACCINE; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL IMMUNITY; CASE CONTROL STUDY; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION PROFILING; GENETIC POLYMORPHISM; HUMAN; IMMUNOPATHOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; TRACHOMA; VACCINATION;

CHLAMYDIA; IMMUNOPATHOLOGY; PROTECTIVE IMMUNITY; TRACHOMA; VACCINE;

ANIMALS; BACTERIAL VACCINES; BLINDNESS; CHLAMYDIA TRACHOMATIS; CLINICAL TRIALS AS TOPIC; EYE; HUMANS; TRACHOMA; VACCINATION;

EID: 84896697403     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.10.016     Document Type: Article

References (100)

1. WHO. Global incidence and prevalence of selected curable sexually transmitted infections - 2008. 2012 [cited; Available from: ]. http://www.who.int/reproductivehealth/publications/rtis/stisestimates/en/index.html%23.
2. Brunham R.C., Rekart M.L. The arrested immunity hypothesis and the epidemiology of chlamydia control. Sex Transm Dis 2008, 35(January (1)):53-54.
3. Rank Roger G., Whittum-Hudson Judith A. Protective immunity to chlamydial genital infection: evidence from animal studies. J Infect Dis 2010, 201(S2):168-177.
4. Darville T., Hiltke Thomas J. Pathogenesis of genital tract disease due to Chlamydia trachomatis. J Infect Dis 2010, 201(S2):114-125.
5. Brunham R.C., Rey-Ladino J. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nat Rev Immunol 2005, 5(February (2)):149-161.
6. Cochrane M., Armitage C.W., O'Meara C.P., Beagley K.W. Towards a Chlamydia trachomatis vaccine: how close are we?. Future Microbiol 2010, 5(December (12)):1833-1856.
7. Karunakaran K.P., Yu H., Foster L.J., Brunham R.C. Development of a Chlamydia trachomatis T cell vaccine. Hum Vaccin 2010, 6(October (10)).
8. Howie S.E., Horner P.J., Horne A.W., Entrican G. Immunity and vaccines against sexually transmitted Chlamydia trachomatis infection. Curr Opin Infect Dis 2011, 24(February (1)):56-61.
9. Brunham R.C., Rappuoli R. Chlamydia trachomatis control requires a vaccine. Vaccine 2013, 31(April (15)):1892-1897.
10. Batteiger Byron E., Xu F., Johnson Robert E., Rekart Michael L. Protective immunity to Chlamydia trachomatis genital infection: evidence from human studies. J Infect Dis 2010, 201(S2):178-189.
11. Gottlieb Sami L., Martin David H., Xu F., Byrne Gerald I., Brunham Robert C. Summary: the natural history and immunobiology of Chlamydia trachomatis genital infection and implications for Chlamydia control. J Infect Dis 2010, 201(S2):190-204.
12. Mabey D.C., Solomon A.W., Foster A. Trachoma. Lancet 2003, 362(July (9379)):223-229.
13. Hu V.H., Harding-Esch E.M., Burton M.J., Bailey R.L., Kadimpeul J., Mabey D.C. Epidemiology and control of trachoma: systematic review. Trop Med Int Health 2010, 15(June (6)):673-691.
14. Mariotti S.P., Pascolini D., Rose-Nussbaumer J. Trachoma: global magnitude of a preventable cause of blindness. Br J Ophthalmol 2009, 93(May (5)):563-568.
15. Harris S.R., Clarke I.N., Seth-Smith H.M., Solomon A.W., Cutcliffe L.T., Marsh P., et al. Whole-genome analysis of diverse Chlamydia trachomatis strains identifies phylogenetic relationships masked by current clinical typing. Nat Genet 2012, March.
16. Hu V.H., Holland M.J., Burton M.J. Trachoma: protective and pathogenic ocular immune responses to Chlamydia trachomatis. PLoS Negl Trop Dis 2013, 7(February (2)):e2020.
17. Jawetz E., Rose L., Hanna L., Thygeson P. Experimental inclusion conjunctivitis in man: measurements of infectivity and resistance. JAMA 1965, 194(November (6)):620-632.
18. Collier L.H., Duke-Elder S., Jones B.R. Experimental trachoma produced by cultured virus. Part II. Br J Ophthalmol 1960, 44(February):65-88.
19. Solomon A.W., Holland M.J., Burton M.J., West S.K., Alexander N.D., Aguirre A., et al. Strategies for control of trachoma: observational study with quantitative PCR. Lancet 2003, 362(August (9379)):198-204.
20. Dawson C., Jawetz E., Hanna L., Rose L., Wood T.R., Thygeson P. Experimental inclusion conjunctivitis in man. II. Partial resistance to reinfection. Am J Epidemiol 1966, 84(November (3)):411-425.
21. Wang S.P., Grayston J.T., Alexander E.R. Trachoma vaccine studies in monkeys. Am J Ophthalmol 1967, 63(May (Suppl. (5))):1615-1630.
22. Taylor H.R. Development of immunity to ocular chlamydial infection. Am J Trop Med Hyg 1990, 42(April (4)):358-364.
23. Grayston J.T., Wang S.P., Yeh L.J., Kuo C.C. Importance of reinfection in the pathogenesis of trachoma. Rev Infect Dis 1985, 7(November-December (6)):717-725.
24. Taylor H.R., Johnson S.L., Prendergast R.A., Schachter J., Dawson C.R., Silverstein A.M. An animal model of trachoma II. The importance of repeated reinfection. Invest Ophthalmol Vis Sci 1982, 23(October (4)):507-515.
25. West S.K., Munoz B., Mkocha H., Hsieh Y.H., Lynch M.C. Progression of active trachoma to scarring in a cohort of Tanzanian children. Ophthalmic Epidemiol 2001, 8(July (2-3)):137-144.
26. Wolle M.A., Munoz B.E., Mkocha H., West S.K. Constant ocular infection with Chlamydia trachomatis predicts risk of scarring in children in Tanzania. Ophthalmology 2009, 116(February (2)):243-247.
27. Bailey R., Duong T., Carpenter R., Whittle H., Mabey D. The duration of human ocular Chlamydia trachomatis infection is age dependent. Epidemiol Infect 1999, 123(December (3)):479-486.
28. Grassly N.C., Ward M.E., Ferris S., Mabey D.C., Bailey R.L. The natural history of trachoma infection and disease in a Gambian cohort with frequent follow-up. PLoS Negl Trop Dis 2008, 2(12):e341.
29. Collier L.H. Experiments with trachoma vaccines. Experimental system using inclusion blennorrhoea virus. Lancet 1961, 1(April (7181)):795-800.
30. Nichols R.L., Bell S.D., Murray E.S., Haddad N.A., Bobb A.A. Studies on trachoma. V. Clinical observations in a field trial of bivalent trachoma vaccine at three dosage levels in Saudi Arabia. Am J Trop Med Hyg 1966, 15(July (4)):639-647.
31. Nichols R.L., Bell S.D., Haddad N.A., Bobb A.A. Studies on trachoma. VI. Microbiological observations in a field trial in Saudi Arabia of bivalent rachoma vaccine at three dosage levels. Am J Trop Med Hyg 1969, 18(September (5)):723-730.
32. Grayston J.T., Woolridge R.L., Wang S.P., Yen C.H., Yang C.Y., Cheng K.H., et al. Field studies of protection from infection by experimental trachoma virus vaccine in preschool-aged children on Taiwan. Proc Soc Exp Biol Med 1963, 112(March):589-595.
33. Woolridge R.L., Grayston J.T., Chang I.H., Cheng K.H., Yang C.Y., Neave C. Field trial of a monovalent and of a bivalent mineral oil adjuvant trachoma vaccine in Taiwan school children. Am J Ophthalmol 1967, 63(May (Suppl. (5))):1645-1650.
34. Sowa S., Sowa J., Collier L.H., Blyth W.A. Trachoma vaccine field trials in The Gambia. J Hyg (Lond) 1969, 67(December (4)):699-717.
35. Collier L.H., Sowa S., Sowa J., Blyth W.A. Experiments with trachoma vaccines: therapeutic effect on established trachoma. Orient Arch Ophthalmol 1969, 1:67-74.
36. Dhir S.P., Agarwal L.P., Detels R., Wang S.P., Grayston J.T. Field trial of two bivalent trachoma vaccines in children of Punjab Indian villages. Am J Ophthalmol 1967, 63(May (Suppl. (5))):1639-1644.
37. Collier L.H., Sowa S., Sowa J. TRIC-agent neonatal conjunctivitis. Lancet 1969, 1(January (7585)):101.
38. Kari L., Whitmire W.M., Crane D.D., Reveneau N., Carlson J.H., Goheen M.M., et al. Chlamydia trachomatis native major outer membrane protein induces partial protection in nonhuman primates: implication for a trachoma transmission-blocking vaccine. J Immunol 2009, 182(June (12)):8063-8070.
39. Kari L., Whitmire W.M., Olivares-Zavaleta N., Goheen M.M., Taylor L.D., Carlson J.H., et al. A live-attenuated chlamydial vaccine protects against trachoma in nonhuman primates. J Exp Med 2011, 208(October (11)):2217-2223.
40. Fraser C.E., McComb D.E., Murray E.S., MacDonald A.B. Immunity to chlamydial infections of the eye. IV. Immunity in owl monkeys to reinfection with trachoma. Arch Ophthalmol 1975, 93(July (7)):518-521.
41. Fan J., Stephens R.S. Antigen conformation dependence of Chlamydia trachomatis infectivity neutralization. J Infect Dis 1997, 176(September (3)):713-721.
42. Bailey R.L., Kajbaf M., Whittle H.C., Ward M.E., Mabey D.C. The influence of local antichlamydial antibody on the acquisition and persistence of human ocular chlamydial infection: IgG antibodies are not protective. Epidemiol Infect 1993, 111(October (2)):315-324.
43. Kari L., Bakios L.E., Goheen M.M., Bess L.N., Watkins H.S., Southern T.R., et al. Antibody signature of spontaneous clearance of Chlamydia trachomatis ocular infection and partial resistance against rechallenge in a nonhuman primate trachoma model. PLoS Negl Trop Dis 2013.
44. Bailey R.L., Holland M.J., Whittle H.C., Mabey D.C. Subjects recovering from human ocular chlamydial infection have enhanced lymphoproliferative responses to chlamydial antigens compared with those of persistently diseased controls. Infect Immun 1995, 63(2):389-392.
45. Holland M., Faal N., Jeffries D., Joof H., Sarr I., Laye M., et al. Human ocular Chlamydia trachomatis disease, infection and immune responses examined using quantitative conjunctival gene expression with intensive longitudinal follow-up and gene co-expression analysis. Chlamydial infections 2010, 145-148. J. Schachter, G.I. Byrne, H. Caldwell, M. Chernesky, I.N. Clarke, D. Mabey (Eds.).
46. Burton M.J., Bailey R.L., Jeffries D., Mabey D.C., Holland M.J. Cytokine and fibrogenic gene expression in the conjunctivas of subjects from a gambian community where trachoma is endemic. Infect Immun 2004, 72(December (12)):7352-7356.
47. Faal N., Bailey R.L., Sarr I., Joof H., Mabey D.C., Holland M.J. Temporal cytokine gene expression patterns in subjects with trachoma identify distinct conjunctival responses associated with infection. Clin Exp Immunol 2005, 142(November (2)):347-353.
48. Faal N., Bailey R.L., Jeffries D., Joof H., Sarr I., Laye M., et al. Conjunctival FOXP3 expression in Trachoma: do regulatory T cells have a role in human ocular Chlamydia trachomatis infection?. PLoS Med 2006, 3(August (8)):e266.
49. Natividad A., Freeman T.C., Jeffries D., Burton M.J., Mabey D.C., Bailey R.L., et al. Human conjunctival transcriptome analysis reveals the prominence of innate defense in Chlamydia trachomatis infection. Infect Immun 2010, 78(November (11)):4895-4911.
50. Burton M.J., Ramadhani A., Weiss H.A., Hu V., Massae P., Burr S.E., et al. Active trachoma is associated with increased conjunctival expression of IL17A and profibrotic cytokines. Infect Immun 2011, 79(December (12)):4977-4983.
51. Onishi R.M., Gaffen S.L. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 2010, 129(March (3)):311-321.
52. Reynolds J.M., Angkasekwinai P., Dong C. IL-17 family member cytokines: regulation and function in innate immunity. Cytokine Growth Factor Rev 2010, 21(December (6)):413-423.
53. Khader S.A., Gaffen S.L., Kolls J.K. Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. Mucosal Immunol 2009, 2(September (5)):403-411.
54. Mi S., Li Z., Yang H.Z., Liu H., Wang J.P., Ma Y.G., et al. Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-{beta}1-dependent and -independent mechanisms. J Immunol 2011, August.
55. Burton M.J., Rajak S.N., Bauer J., Weiss H.A., Tolbert S.B., Shoo A., et al. Conjunctival transcriptome in scarring trachoma. Infect Immun 2011, 79(January (1)):499-511.
56. Gall A., Horowitz A., Joof H., Natividad A., Tetteh K., Riley E., et al. Systemic effector and regulatory immune responses to chlamydial antigens in Trachomatous Trichiasis. Front Microbiol 2011, 201(February):10-12.
57. Gao B., Radaeva S. Natural killer and natural killer T cells in liver fibrosis. Biochim Biophys Acta 2013, 1832(July (7)):1061-1069.
58. Wolk K., Sabat R. Interleukin-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev 2006, 17(October (5)):367-380.
59. Horowitz A., Newman K.C., Evans J.H., Korbel D.S., Davis D.M., Riley E.M. Cross-talk between T cells and NK cells generates rapid effector responses to Plasmodium falciparum-infected erythrocytes. J Immunol 2010, 184(June (11)):6043-6052.
60. Lu C., Holland M.J., Gong S., Peng B., Bailey R.L., Mabey D.W., et al. Genome-wide identification of Chlamydia trachomatis antigens associated with Trachomatous Trichiasis. Invest Ophthalmol Vis Sci 2012, March.
61. Skwor T., Kandel R.P., Basravi S., Khan A., Sharma B., Dean D. Characterization of humoral immune responses to chlamydial heat shock protein 60, protease-like activity factor and hypothetical protein CT795 in inflammatory and severe trachoma. Invest Ophthalmol Vis Sci 2010, May.
62. Peeling R.W., Bailey R.L., Conway D.J., Holland M.J., Campbell A.E., Jallow O., et al. Antibody response to the 60-kDa chlamydial heat-shock protein is associated with scarring trachoma. J Infect Dis 1998, 177(January (1)):256-259.
63. Holland M.J., Bailey R.L., Hayes L.J., Whittle H.C., Mabey D.C. Conjunctival scarring in trachoma is associated with depressed cell-mediated immune responses to chlamydial antigens. J Infect Dis 1993, 168(6):1528-1531.
64. Wynn T.A. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004, 4(August (8)):583-594.
65. Allen J.E., Wynn T.A. Evolution of Th2 immunity: a rapid repair response to tissue destructive pathogens. PLoS Pathog 2011, (May (5)):e1002003.
66. Conway D.J., Holland M.J., Campbell A.E., Bailey R.L., Krausa P., Peeling R.W., et al. HLA class I and II polymorphisms and trachomatous scarring in a Chlamydia trachomatis-endemic population. J Infect Dis 1996, 174(3):643-646.
67. Holland M.J., Jeffries D., Pattison M., Korr G., Gall A., Joof H., et al. Pathway-focused arrays reveal increased matrix metalloproteinase-7 (matrilysin) transcription in trachomatous trichiasis. Invest Ophthalmol Vis Sci 2010, 51(August (8)):3893-3902.
68. Hu V.H., Weiss H.A., Ramadhani A.M., Tolbert S.B., Massae P., Mabey D.C., et al. Innate immune responses and modified extracellular matrix regulation characterize bacterial infection and cellular/connective tissue changes in scarring trachoma. Infect Immun 2012, 80(January (1)):121-130.
69. Skwor T.A., Atik B., Kandel R.P., Adhikari H.K., Sharma B., Dean D. Role of secreted conjunctival mucosal cytokine and chemokine proteins in different stages of trachomatous disease. PLoS Negl Trop Dis 2008, 2(7):e264.
70. Conway D.J., Holland M.J., Bailey R.L., Campbell A.E., Mahdi O.S., Jennings R., et al. Scarring trachoma is associated with polymorphism in the tumor necrosis factor alpha (TNF-alpha) gene promoter and with elevated TNF-alpha levels in tear fluid. Infect Immun 1997, 65(3):1003-1006.
71. Mozzato-Chamay N., Mahdi O.S., Jallow O., Mabey D.C., Bailey R.L., Conway D.J. Polymorphisms in candidate genes and risk of scarring trachoma in a Chlamydia trachomatis--endemic population. J Infect Dis 2000, 182(5):1545-1548.
72. Mozzato-Chamay N., Corbett E.L., Bailey R.L., Mabey D.C., Raynes J., Conway D.J. Polymorphisms in the IkappaB-alpha promoter region and risk of diseases involving inflammation and fibrosis. Genes Immun 2001, 2(May (3)):153-155.
73. Natividad A., Wilson J., Koch O., Holland M.J., Rockett K., Faal N., et al. Risk of trachomatous scarring and trichiasis in Gambians varies with SNP haplotypes at the interferon-gamma and interleukin-10 loci. Genes Immun 2005, 24(Mar):1-9.
74. Natividad A., Holland M.J., Rockett K.A., Forton J., Faal N., Joof H.M., et al. Susceptibility to sequelae of human ocular chlamydial infection associated with allelic variation in IL10 cis-regulation. Hum Mol Genet 2008, 17(January (2)):323-329.
75. Burton M.J., Rajak S.N., Ramadhani A., Weiss H.A., Habtamu E., Abera B., et al. Post-operative recurrent trachomatous trichiasis is associated with increased conjunctival expression of S100A7 (psoriasin). PLoS Negl Trop Dis 2012, 6(12):e1985.
76. Natividad A., Hull J., Luoni G., Holland M., Rockett K., Joof H., et al. Innate immunity in ocular Chlamydia trachomatis infection: contribution of IL8 and CSF2 gene variants to risk of trachomatous scarring in Gambians. BMC Med Genet 2009, 10:138.
77. Natividad A., Hanchard N., Holland M.J., Mahdi O.S., Diakite M., Rockett K., et al. Genetic variation at the TNF locus and the risk of severe sequelae of ocular Chlamydia trachomatis infection in Gambians. Genes Immun 2007, 8(June (4)):288-295.
78. Atik B., Skwor T.A., Kandel R.P., Sharma B., Adhikari H.K., Steiner L., et al. Identification of novel single nucleotide polymorphisms in inflammatory genes as risk factors associated with trachomatous trichiasis. PLoS ONE 2008, 3(10):e3600.
79. Bobo L., Novak N., Mkocha H., Vitale S., West S., Quinn T.C. Evidence for a predominant proinflammatory conjunctival cytokine response in individuals with trachoma. Infect Immun 1996, 64(8):3273-3279.
80. Wong T.T., Mead A.L., Khaw P.T. Prolonged antiscarring effects of ilomastat and MMC after experimental glaucoma filtration surgery. Invest Ophthalmol Vis Sci 2005, 46(June (6)):2018-2022.
81. Abu el-Asrar A.M., Geboes K., Tabbara K.F., al-Kharashi S.A., Missotten L., Desmet V. Immunopathogenesis of conjunctival scarring in trachoma. Eye (Lond) 1998, 12(Pt 3a):453-460.
82. Ramsey K.H. Alternative mechanisms of pathogenesis. Chlamydia: genomics and pathogenesis 2006, 435-474. Horizon Bioscience, Wymondham, Norfolk, UK. P. Bavoil, P.B. Wyrick (Eds.).
83. Salamonsen L.A. Role of proteases in implantation. Rev Reprod 1999, 4(June (1)):11-22.
84. Hu J., Van den Steen P.E., Sang Q.X., Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Disc 2007, 6(June (6)):480-498.
85. Chakrabarti S., Patel K.D. Matrix metalloproteinase-2 (MMP-2) and MMP-9 in pulmonary pathology. Exp Lung Res 2005, 31(July-August (6)):599-621.
86. Wang J.C. Importance of plasma matrix metalloproteinases (MMP) and tissue inhibitors of metalloproteinase (TIMP) in development of fibrosis in agnogenic myeloid metaplasia. Leukemia Lymphoma 2005, 46(September (9)):1261-1268.
87. Wynn T.A. Cellular and molecular mechanisms of fibrosis. J Pathol 2008, 214(June (2)):199-210.
88. Parks W.C., Wilson C.L., Lopez-Boado Y.S. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004, 4(August (8)):617-629.
89. Wong T.T., Sethi C., Daniels J.T., Limb G.A., Murphy G., Khaw P.T. Matrix metalloproteinases in disease and repair processes in the anterior segment. Surv Ophthalmol 2002, 47(May-June (3)):239-256.
90. El-Asrar A.M., Geboes K., Al-Kharashi S.A., Al-Mosallam A.A., Missotten L., Paemen L., et al. Expression of gelatinase B in trachomatous conjunctivitis. Br J Ophthalmol 2000, 84(June (1)):85-91.
91. Natividad A., Cooke G., Holland M.J., Burton M.J., Joof H.M., Rockett K., et al. A coding polymorphism in matrix metalloproteinase 9 reduces risk of scarring sequelae of ocular Chlamydia trachomatis infection. BMC Med Genet 2006, 7:40.
92. Burton M.J., Bailey R.L., Jeffries D., Rajak S.N., Adegbola R.A., Sillah A., et al. Conjunctival expression of matrix metalloproteinase and proinflammatory cytokine genes after trichiasis surgery. Invest Ophthalmol Vis Sci 2010, 51(July (7)):3583-3590.
93. Burton M.J., Jeffries D., Rajak S.N., Adegbola R.A., Sillah A., Mabey D.C.W., et al. Conjunctival expression of matrix metalloproteinase and pro-inflammatory cytokine genes following trichiasis surgery. IOVS 2009.
94. Abu El-Asrar A.M., Al-Kharashi S.A., Missotten L., Geboes K. Expression of growth factors in the conjunctiva from patients with active trachoma. Eye (Lond) 2006, 20(March (3)):362-369.
95. Brunham R.C., Kuo C.C., Cles L., Holmes K.K. Correlation of host immune response with quantitative recovery of Chlamydia trachomatis from the human endocervix. Infect Immun 1983, 39(3):1491-1494.
96. Debattista J., Timms P., Allan J., Allan J. Reduced levels of gamma-interferon secretion in response to chlamydial 60kDa heat shock protein amongst women with pelvicinflammatory disease and a history of repeated Chlamydia trachomatis infections. Immunol Lett 2002, 81(3):205-210.
97. Cohen C.R., Nguti R., Bukusi E.A., Lu H., Shen C., Luo M., et al. Human immunodeficiency virus type1-infected women exhibit reduced interferon-gamma secretion after Chlamydia trachomatis stimulation of peripheral blood lymphocytes. J Infect Dis 2000, 182(6):1672-1677.
98. Kimani J., MacLean I.W., Bwayo J.J., et al. Risk factors for Chlamydia trachomatis pelvic inflammatory disease among sex workers in Nairobi: Kenya. J Infect Dis 1996, 173(6):1437-1444.
99. Hu V.H., Weiss H.A., Massae P., Courtright P., Makupa W., Mabey D.C., et al. In vivo confocal microscopy in scarring trachoma. Ophthalmology 2011, 118(November (11)):2138-2146.
100. Hafner L.M., Wilson D.P., Timms P. Development status and future prospects for a vaccine against Chlamydia trachomatis infection. Vaccine 2013, [in this issue].